cyclopentane has been researched along with Kahler Disease in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Antonangeli, F; Capuano, C; Cippitelli, M; Fionda, C; Galandrini, R; Mekhloufi, A; Molfetta, R; Paolini, R; Petillo, S; Petrucci, MT; Pighi, C; Santoni, A; Soriani, A; Zingoni, A | 1 |
| Ehrenschwender, M; El-Mesery, M; Leich, E; Rauert-Wunderlich, H; Rosenthal, T; Schlosser, A; Schreder, M; Siegmund, D; Stühmer, T; Wajant, H | 1 |
| Anderson, KC; Cang, Y; Hideshima, T; Ho, M; Liu, J; Peng, Z; Song, T; Tai, YT; Wang, S; Xing, L; Zhou, W | 1 |
| Bargou, RC; Giner, T; Maier, E; Rauert-Wunderlich, H; Siegmund, D; Stühmer, T; Wajant, H | 1 |
| Bernal, L; Boise, LH; Chen, J; Gu, Y; Harvey, RD; Kaufman, JL; Lonial, S; Matulis, SM; Sun, SY; Torre, C | 1 |
| Gu, Z; Huang, J; Thomas, GS; Tricot, G; Xu, H; Yang, Y; Zhan, F; Zhou, Y | 1 |
| Berger, AJ; Dezube, BJ; Diefenbach, C; Faessel, HM; Harvey, RD; Hua, Z; Jakubowiak, AJ; Kelly, K; Lebovic, D; Lonial, S; Mulligan, G; O'Connor, OA; Orlowski, RZ; Shah, JJ; Smith, MR; Tirrell, S | 1 |
| Choi, SH; Hong, EH; Kim, MN; Kim, MS; Kim, SH; Kim, YS; Lee, JH; Lee, SO; Park, KH; Woo, JH; Yi, H | 1 |
| Anderson, KC; Delmore, J; Jakubikova, J; Kastritis, E; Klippel, S; Laubach, J; McMillin, D; Mitsiades, CS; Ooi, M; Richardson, PG | 1 |
1 trial(s) available for cyclopentane and Kahler Disease
| Article | Year |
|---|---|
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Cyclopentanes; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; NEDD8 Protein; Neoplasm Recurrence, Local; Pyrimidines; Retreatment; Treatment Outcome; Ubiquitins | 2016 |
8 other study(ies) available for cyclopentane and Kahler Disease
| Article | Year |
|---|---|
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
Topics: Aged; Aged, 80 and over; Cell Degranulation; Cell Line, Tumor; Cyclopentanes; Female; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class I; Humans; Immunologic Factors; Immunomodulation; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Ligands; Male; Middle Aged; Multiple Myeloma; NEDD8 Protein; NK Cell Lectin-Like Receptor Subfamily K; Plasma Cells; Promoter Regions, Genetic; Pyrimidines; Up-Regulation | 2021 |
The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1
Topics: Adult; Aged; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Survival; Cyclopentanes; Female; Humans; Male; Middle Aged; Multiple Myeloma; Necrosis; NF-kappa B; Oligopeptides; Pyrimidines; Receptors, Tumor Necrosis Factor, Type I; Signal Transduction; Tumor Necrosis Factor-alpha; Ubiquitin-Activating Enzymes | 2019 |
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; COP9 Signalosome Complex; CRISPR-Cas Systems; Cyclopentanes; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Immunologic Factors; Multiple Myeloma; Peptide Hydrolases; Prognosis; Proteolysis; Pyrimidines; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; Ubiquitination | 2019 |
The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFκB transcription factors.
Topics: Amides; Apoptosis; Blotting, Western; Cell Line; Cell Survival; Cyclopentanes; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Microscopy, Fluorescence; Multiple Myeloma; NF-kappa B; Nitriles; Pyrimidines; RNA, Small Interfering; Signal Transduction; Sulfones; Thiophenes | 2013 |
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Humans; Multiple Myeloma; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Ubiquitin-Activating Enzymes; Up-Regulation | 2014 |
NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Topics: Antineoplastic Agents; Apoptosis; Bortezomib; CDC2-CDC28 Kinases; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclopentanes; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Multiple Myeloma; NEDD8 Protein; Proteolysis; Pyrimidines; Signal Transduction; Ubiquitins | 2015 |
Successful salvage therapy with inhaled zanamivir in a patient with peramivir-resistant pandemic influenza A (H1N1) 2009 virus.
Topics: Acids, Carbocyclic; Administration, Inhalation; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Treatment Outcome; Virus Shedding; Zanamivir | 2011 |
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.
Topics: Acetates; Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cyclopentanes; Drug Synergism; Humans; Leukocytes, Mononuclear; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Multiple Myeloma; Oxylipins; Plant Growth Regulators | 2012 |